Abstract
TheBamHI Z EBV replication activator (ZEBRA) protein is involved in the switch from latency to productive cycle of Epstein-Barr virus. A recombinant ZEBRA protein was synthesized and assessed in enzymelinked immunosorbent assay (ELISA) for serum IgG response in nasopharyngeal carcinoma (NPC) patients. In 100 NPC serum samples that were positive for IgA to the EBV viral capsid antigen (VCA), 75% had IgG anti-ZEBRA antibodies. In contrast, only 3/83 (3.6%) serum samples from healthy donors and 2/50 (4%) from other cancers were positive for IgG to ZEBRA. Interestingly, in a selected group of 100 NPC sera negative for IgA to VCA, 25% contained IgG anti-ZEBRA antibodies. This suggests that the ELISA for IgG anti-ZEBRA may also identify earlier cases of NPC not detected by the conventional immunofluorescence test for IgA to VCA.
This is a preview of subscription content, log in via an institution to check access.
References
Desgranges G, Wolf H, The G de, Shanmugaratnam K, Ellouz R, Cammoun N, Klein G, Lennert K, Munoz N, Hansen H zur (1975) Nasopharyngeal carcinoma. X. Presence of Epstein-Barr genomes in the epithelial cell tumors from high and medium risk areas. Int J Cancer 16:7
Foong YT, Cheng HM, Sam CK, Dillner J, Hinderer W, Prasad U (1990) Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 45:1061
Grogan E, Jenson H, Countryman J, Heston L, Gradoville L, Miller G (1987) Transfection of a rearranged viral DNA fragment, WZhet, stably converts Epstein-Barr viral infection to productive infection in lymphoid cells. Proc Natl Acad Sci USA 84:1332
Henderson BE, Louie E, Bugdanoff E, Henle W, Alenat B, Henle G (1974) Antibodies to herpes group viruses in patients with nasopharyngeal carcinoma and other head and neck cancers. Cancer Res 34:1207
Henle G, Henle W (1976) Epstein-Barr virus specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17:1
Henle G, Henle W, Klein G (1971) Demonstration of 2 distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer 8:272
Henle W, Henle G, Ho JHC, Burtin P, Cachin Y, Clifford P, Schryver A de, The G de, Diehl V, Klein G (1970) Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms and control groups. J Natl Cancer Inst 44:225
Hinderer W, Nebel-Schickel H, Horn J, Vornhagen R, Sonneborn HH, Gorgievski-Hrisoho M, Siegl G, Faerber I, Wutzler P, Wolf H (1990) Recombinant EBV antigens and their diagnostic value. In: Epstein-Barr virus and human disease. Humana Press, Clifton, New Jersey, p 123
Joab I, Nicolas JC, Schwaab G, The G de, Clausse B, Perricaudet M, Zeng Y (1991) Detection of anti-Epstein-Barr virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer 48:647
Klein G, Giovanella BC, Lindahl T, Fialkow PJ, Singh S, Stehlin JS (1974) Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci USA 71:4737
Lin TM, Yang CS, Ho SW, Chiou JF, Wang CH, Tu SM, Chen KP, Ito Y, Kawamura A Jr, Hirayama T (1971) Antibodies to herpes type virus in nasopharyngeal carcinoma and control groups in Taiwan. In: Recent advances in human tumor virology and immunology, University of Tokyo Press, Tokyo, p 309
Miller G, Taylor N, Kolman J, Baumann R, Katz D, Himmelfarb H, Carey M, Ptashne M (1990) How ZEBRA, a weak transactivator, exerts strong biological effects, In: Epstein-Barr virus and human disease. Humana Press, Clifton, New Jersey, p 27
Prasad U, Ablashi DV, Prathab K, Yadav M, Singaram SP, Singh P, Singh J (1983) Problem of occult primary in nasopharyngeal carcinoma. In: Nasopharyngeal carcinoma: current concepts. University Malaya, Kuala Lumpur, p 11
Prasad U, Rampal L (1992) Descriptive epidemiology of nasopharyngeal carcinoma in Peninsular Malaysia. Cancer Causes Controls 3:179
Sam CK, Prasad U, Pathmanathan R (1989) Serological marker in the diagnosis of histopathological types of nasopharyngeal carcinoma. Eur J Sur Oncol 15:357
Schryver A de, Friberg S Jr, Klein G, Henle W, Henle G, The G de, Clifford P (1969) Epstein-Barr virus associated antibody patterns in carcinoma of the post-nasal space. Clin Exp Immunol 5:443
Schryver A de, Klein G, Henle G, Cameron HM, Santesson L, Clifford P (1972) Epstein-Barr virus associated serology in malignant disease: antibody levels to viral capsid antigens (VCA), membrane antigens (MA) and early antigens (EA) in patients with various neoplastic conditions. Int J Cancer 9: 353
Schryver A de, Klein G, Henle W, Henle G (1974) Epstein-Barr virus associated antibodies in Caucasian patients with carcinoma of the nasopharyx and in the long-term survivors after treatment. Int J Cancer 13:319
Se Thoe SY, Sam CK, Cheng HM, Prasad U (1989) Improved sensitivity of detection by avidin-biotin complex (ABC) immunocytochemistry in Epstein-Barr virus serology. J Med Virol 29:311
Shanmugaratnam K (1978) Variatiins in nasopharyngeal cancer incidence among specific Chinese communities (dialect groups) in Singapore. In: NPC-Etiology and Control. IARC Sci Publ 20:191
Waterhouse J, Muir CS, Shanmugaratnam K, Powell J (1982) Cancer incidents in five continents. IARC Sci Publ 42:294
Yeh S (1967) The relative frequency of nasopharynx and accessory sinuses in Chinese in Taiwan. In: Cancer of the nasopharynx. UICC Monograph Series. Munksgaard, Copenhagen, p 54
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mathew, A., Cheng, HM., Sam, CK. et al. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. Cancer Immunol Immunother 38, 68–70 (1994). https://doi.org/10.1007/BF01517172
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01517172